PPARG and liposarcoma: PPARγ has shown promise in therapy promoting terminal differentiation and apoptosis in a variety of malignancies, including liposarcoma, breast cancer, leukemia, gastric cancer, non‐small cell lung cancer, and prostate cancer [19–27].